Severity score for hereditary hemorrhagic telangiectasia

Area of Science:

• Medical research
• Clinical assessment
• Genetics and rare diseases

Background:

• Hereditary Hemorrhagic Telangiectasia (HHT) is a rare genetic disorder.
• A validated disease severity score for HHT is lacking.
• Such a score is crucial for assessing disease burden and clinical trial design.

Purpose of the Study:

• To introduce the first HHT-specific disease severity score, the HHT-score.
• To evaluate the association between the HHT-score and adverse outcomes in HHT patients.

Main Methods:

• Collected data from 525 HHT patients in the Brain Vascular Malformation Consortium (BVMC) HHT Project.
• Developed the HHT-score based on organ arteriovenous malformations, chronic bleeding, and severe organ involvement.
• Categorized patients into mild, moderate, and severe disease groups based on their HHT-score.

Main Results:

• The HHT-score demonstrated significant differences in adverse outcomes across severity groups (mild 49.6%, moderate 65.8%, severe 89.5%).
• Moderate and severe HHT-score categories were associated with significantly higher risks of adverse outcomes compared to the mild category, even after adjusting for age and gender.

Conclusions:

• The HHT-score represents a promising initial step towards a global measure of HHT disease severity.
• Further validation studies are necessary to confirm the HHT-score's utility and reliability in clinical practice.